The tyrosine kinase inhibitor Gleevec, currently used to treat cancers such as chronic myeloid leukemia, can also function as an antiviral drug to treat poxvirus infections (pages 731–739).
This is a preview of subscription content, log in via an institution to check access.
Ann Thomson
References
Deininger, M. et al. Blood 105, 2640–2653 (2005).
Ren, R. Nat. Rev. Cancer 5, 172–183 (2005).
Pardanani, A. & Tefferi, A. Blood 104, 1931–1939 (2004).
Reeves, P.M. et al. Nat. Med. 11, 731–739 (2005).
Smith, G.L. & Law, M. Vir. Res. 106, 189–197 (2004).
Frischknecht, F. et al. Nature 401, 926–929 (1999).
Newsome, T.P. et al. Science 306, 124–129 (2004).
Ward, B.M & Moss, B. J. Virol. 78, 2486–2493 (2004).
Andrade, A.A. et al. Biochem. J. 381, 437–446 (2004).
Yang, H. et al. J. Clin. Invest. 115, 379–387 (2005).
McFadden, G. Nat. Rev. Immunol. 3, 201–213 (2005).
O'Hare, T. et al. Cancer Cell 7, 117–119 (2005).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McFadden, G. Gleevec casts a pox on poxviruses. Nat Med 11, 711–712 (2005). https://doi.org/10.1038/nm0705-711
Issue Date:
DOI: https://doi.org/10.1038/nm0705-711
- Springer Nature America, Inc.